Search Results
May 31, 2026, 20:00 ET 德昇濟醫藥在ASCO 2026公布Elisrasib（D3S-001）一線治療數據；新一代KRAS G12C抑制劑在初治NSCLC中展現裡程碑式療效
Elisrasib單藥在KRAS G12C突變晚期NSCLC一線治療中實現78.0%的客觀緩解率（ORR），中位無進展生存期（PFS）為12.4個月（n=41），且在各PD-L1表達水平人群中療效一致Elisrasib聯合帕博利珠單抗在一線治療中實現81.3%的ORR（n=48），12個月PFS率達53.7%上海2026年6月1日 /美通社/ -- 德昇濟醫藥，一家致力於創新腫瘤療法開發的全球臨床階段生物技術公司，今日宣布其新一代KRAS
More news about: 德昇濟醫藥（D3 Bio）
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
efficacy-evaluable patients, an ORR 81.3% was observed across all PD-L1 expression levels, with ORR of 70.6% in patients with PD-L1 TPS <1% (N=17), 72.7% in patients with PD-L1 TPS of 1% to 49% (N=11), and 95.0% in patients with PD-L1 TPS ≥50% (N=20), respectively. The overall DCR was 97.9%. The median
More news about: D3 Bio
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
65.2% patients had NSCLC tumors demonstrating PD-L1 TPS < 1% and 34.8% had TPS 1–49%.In the IBI363 3→1.5 mg/kg Dose Group, ORR Exceeded 80% in the First-line Treatment of NSCLC, Across Histologies and Particularly in PD-L1 Negative or Low ExpressionPreliminary
More news about: Innovent Biologics
May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability
More news about: ImmVira Group
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Protein)IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to
More news about: Innovent Biologics
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at American Society of Clinical Oncology (ASCO) 2026.
More news about: TiumBio
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
notice.References 1. Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy,
More news about: Servier Pharmaceuticals
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
subgroupsOS benefit with ivonescimab was observed consistently regardless of PD-L1 expression status: HR=0.68 in the PD-L1 TPS ≥1% subgroup and HR=0.64 in the TPS <1% subgroup; HR=0.67 in the PD-L1 TPS 1–49% subgroup and HR=0.64 in the TPS ≥50% subgroup.The OS benefit was also consistent
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose
More news about: Johnson & Johnson
May 31, 2026, 00:13 ET Huawei è stata riconosciuta come Leader nel Gartner® Magic Quadrant™ 2026 dedicato alle infrastrutture LAN aziendali cablate e wireless per il quarto anno consecutivo
end-to-end e osservabilità dell'esperienza. Grazie a un processo decisionale globale basato su IA e alla localizzazione dei guasti a livello di minuti, l'80% dei problemi wireless viene risolto automaticamente.Guardando al futuro, Huawei continuerà a innovare partendo dalle esigenze dei clienti e ad
More news about: Huawei
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
other study reported results for golidocitinib, a JAK1-selective inhibitor, combined with an anti-PD-1 antibody as a first-line treatment for PD-L1-positive, advanced NSCLC without driver mutations.
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
OptiTROP-Lung05是一項隨機、開放性、多中心III期臨床研究，旨在評估蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比帕博利珠單抗單藥一線治療PD-L1 TPS≥1%的局部晚期或轉移性NSCLC的有效性和安全性。期中分析結果表明，相較於帕博利珠單抗單藥，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗可顯著延長無進展生存期(PFS)並降低疾病進展或死亡風險，風險比(HR)為0.35；在預設的各亞組中(包括PD-L1表達水平、組織學類型)均表現出一致的PFS獲益，PD-L1 TPS≥50%和1%-49%人群的PFS HR值分別為0.47和0.28；非鱗狀和鱗狀人群的PFS
More news about: 科倫博泰
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
ratio (HR) of 0.35. Consistent PFS benefits were observed across all prespecified subgroups, including by PD-L1 expression level and histological type, with PFS HRs of 0.47 and 0.28 for the PD-L1 TPS ≥50% and 1–49% subgroups, respectively, and PFS HRs of 0.28 and 0.44 for the non-squamous and squamous
More news about: Kelun-Biotech
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
origin.Expression exceeds other established and emerging ADC targets.SCLC – SEZ6 expression was at least 3-fold higher than HER2, B7-H3, DLL3, PD-L1 and PD-1.Prostate neuroendocrine carcinoma – SEZ6 expression was 2- to 6-fold higher than B7-H3, DLL3 and TROP2.Among SCLC
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 11:38 ET Acción local para proteger a nuestra juventud de la adicción a la nicotina
proteger a nuestros jóvenes del control de la adicción a la nicotina y garantizar un futuro más saludable y libre de humo para todos", dijo la Dra. Jane L. Delgado, presidenta y directora ejecutiva de la Healthy Americas Foundation.Según la NLC y la HAF, las ciudades cuentan con múltiples vías para
More news about: Healthy Americas Foundation (HAF)
May 30, 2026, 11:03 ET Local Action to Protect Our Youth from Nicotine Addiction
these policies, we can protect our young people from the grip of nicotine addiction and ensure a healthier, smoke-free future for all," said Dr. Jane L. Delgado, President and CEO of the Healthy Americas Foundation.According to the NLC and HAF, cities have multiple pathways to act, even in states
More news about: Healthy Americas Foundation (HAF)
May 30, 2026, 06:36 ET Chandigarh University Research Scientist Receives Startup Research Grant of Rs 24 Lakhs
said, "Our project is titled Elucidating the Role of DNA Methylation under Elevated CO2 and Temperature During Grain Filling in Wheat (Triticum aestivum L) is primarily aimed at understanding how DNA methylation patterns change under combined elevated CO2 (carbon-dioxide) and temperature stress during the
More news about: Chandigarh University
May 30, 2026, 00:30 ET 2026 ASCO | 蘆康沙妥珠單抗(sac-TMT) III期OptiTROP-Lung05研究成果於ASCO口頭報告和《柳葉刀》同步發佈
2026年5月30日，四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」 6990.HK)宣佈，在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上，同濟大學附屬東方醫院周彩存教授以口頭報告形式公佈了TROP2 ADC蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊®)聯合帕博利珠單抗(可瑞達®[1]，默沙東的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體1(PD-L1)腫瘤細胞陽性比例分數(TPS)≥1%非小細胞肺癌(NSCLC)的III期OptiTROP-Lung05研究結果(摘要編號#8506，肺癌-轉移性非小細胞)。
More news about: 科倫博泰
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
(KEYTRUDA®[1], MSD's anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor Caicun Zhou from Shanghai East
More news about: Kelun-Biotech
May 29, 2026, 17:32 ET Harford Mutual Insurance Group Announces Board Reelections Following Annual Meeting
The board members reelected were Theodore M. Alexander III, Donald C. Fry, Sandra L. Rich, and Abigail E. Smith. Alexander and Rich were reelected to serve three-year terms. Fry, who currently serves as board chair, and Smith were reelected
More news about: Harford Mutual Insurance Group
May 29, 2026, 15:09 ET Kathy Yang de Hon Hai Technology Group (Foxconn) figure parmi les femmes d'affaires les plus puissantes de 2026 selon Fortune
MPW 2026, établie par les rédacteurs de Fortune, est basée sur la taille et la santé des entreprises ou des P&L des dirigeants, mesurées par des données financières sur 12 mois et trois ans, ainsi que sur leur influence, leur innovation, leurs trajectoires de
More news about: Hon Hai Technology Group (Foxconn)
May 29, 2026, 14:00 ET RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations,
More news about: Johnson & Johnson
May 29, 2026, 12:53 ET Tigé Z3 Named 2026 Top Product, the Only Wakesurf Boat on Boating Industry's List
Audison Pro marine audio system, a closed-cooled 6.2L Indmar Raptor engine, a dedicated surf locker, and the deepest freeboard and largest cockpit in its class. On competing boats, most of these features
More news about: Tige Boats Inc
May 29, 2026, 12:25 ET KIMPTON ASHBEL NEW YORK - PARK AVENUE REINTERPRETS THE CLASSIC MANHATTAN TOWNHOUSE THROUGH A DESIGN-LED LENS
architecture, fashion, and contemporary culture."With Kimpton Ashbel, our goal was to create a hotel that feels lived-in rather than staged," said Sofia L. Vandaele, Regional Director of Operations for IHG Luxury & Lifestyle in New York. "The design encourages guests to slow down and settle in, whether
More news about: Kimpton Ashbel New York - Park Avenue
May 29, 2026, 12:24 ET Haier Biomedical obtiene el primer lugar por categoría doble en el informe mundial de Euromonitor sobre equipos de laboratorio para ciencias biológicas, con lo que finaliza su ampliación mundial en tres fases
e-en-el-informe-mundial-de-euromonitor-sobre-equipos-de-laboratorio-para-ciencias-biologicas-con-lo-que-finaliza-su-ampliacion-mundial-en-tres-fases-302785912.htmlFUENTE Haier Biomedical
More news about: Haier Biomedical